Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
353 studies found for:    "Oligodendroglioma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours
Condition: Oligodendrogliomas
Intervention:
2 Recruiting Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Conditions: Oligodendroglioma;   Oligoastrocytoma
Intervention: Drug: Palbociclib
3 Completed Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Conditions: Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention: Drug: Temozolomide
4 Completed Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
Conditions: Oligoastrocytoma, Mixed;   Anaplastic Oligodendroglioma
Intervention: Drug: Temozolomide
5 Terminated
Has Results
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Conditions: Astrocytoma;   Glioma;   Oligodendroglioma
Interventions: Drug: Irinotecan Hydrochloride (HCI) Treatment;   Drug: Continued Irinotecan Hydrochloride (HCI) Treatment
6 Completed Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim;   Drug: busulfan;   Drug: lomustine;   Drug: procarbazine hydrochloride;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
7 Active, not recruiting Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
Conditions: CNS Cancer;   CNS BRAIN
Intervention: Drug: temozolomide followed by high dose busulfan and thiotepa
8 Completed Temozolomide in Treating Patients With Anaplastic Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: temozolomide
9 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
10 Active, not recruiting Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma
Conditions: Central Nervous System Tumors;   Brain Tumor
Intervention: Drug: temozolomide
11 Completed Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lomustine;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
12 Active, not recruiting Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
13 Completed Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lomustine;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
14 Recruiting Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma
Condition: Glioma : Oligodendroglioma or Astrocytoma
Intervention: Device: Molecular and cellular tumor print Medical Device (ProTool)
15 Active, not recruiting
Has Results
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Neoplasm
Interventions: Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
16 Not yet recruiting Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
Conditions: Glioblastoma;   Oligodendroglioma;   Anaplastic Oligodendroglioma
Interventions: Drug: RRx-001 dose escalation with TMZ + RT;   Radiation: Radiation;   Drug: Fixed dose Temozolomide (75 mg/m2);   Drug: Fixed RRx-001 weekly;   Drug: Staged TMZ and RRx-001 escalation in maintenance stage;   Drug: TMZ Maintenance
17 Recruiting Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Conditions: Adult Anaplastic Oligodendroglioma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Oligoastrocytoma;   Recurrent Adult Brain Neoplasm
Interventions: Drug: Carboplatin;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mannitol;   Drug: Melphalan;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
18 Completed Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide
Conditions: Anaplastic Astrocytoma;   Oligodendroglioma;   Oligoastrocytoma
Interventions: Drug: Temozolomide;   Radiation: Focal radiotherapy
19 Terminated Treatment Strategy for Low-grade Gliomas
Conditions: Astrocytomas;   Oligodendrogliomas;   Oligoastrocytoma
Interventions: Radiation: Radiation therapy;   Drug: Temozolomide
20 Completed Neural Basis of Language Processing
Conditions: Oligoastrocytoma;   Astrocytoma;   Oligodendroglioma
Interventions: Device: fMRI;   Procedure: tractography;   Other: neuropsychological examination

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.